BridgeMD
Tests treatment safety and results for Crohn's Disease
Official title A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov ID: NCT06233461
What this study is testing
What is TAK-279?
TAK-279 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for crohn's disease.
Also referred to as Zasocitinib.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is \>=19...
- Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.
- Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced...
You likely can't join if
- Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease...
- Have complications of CD that might require surgery during the study.
- Participants with a current ostomy.
- Participants who have failed 3 or more classes of advanced therapies.
The study team makes the final eligibility decision.
Where it's taking place
- Murrieta, California, United States
- Orange, California, United States
- Clearwater, Florida, United States
- Lakeland, Florida, United States
- Miami Lakes, Florida, United States
- Naples, Florida, United States
- Orlando, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Decatur, Georgia, United States
- Iowa City, Iowa, United States
- Kansas City, Kansas, United States
- Louisville, Kentucky, United States
- Glen Burnie, Maryland, United States
- Liberty, Missouri, United States
- Las Vegas, Nevada, United States
- New York, New York, United States
- Rochester, New York, United States
- Mentor, Ohio, United States
- Providence, Rhode Island, United States
+ 148 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Murrieta, California, United States; Orange, California, United States; Clearwater, Florida, United States; Lakeland, Florida, United States; Miami Lakes, Florida, United States; Naples, Florida, United States and 162 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.